AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36508217 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 720
Study 36508217 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisectoral agriculture and livelihood intervention
Number of subjects: 720
Study 36508217 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 720
Study 36508251 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiorehabilitation with Virtual Reality (VR)
Number of subjects: 0
Study 36508251 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy (Control)
Number of subjects: 0
Study 36508251 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiorehabilitation with VR
Number of subjects: 0
Study 36508302 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 36508302 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin, Vinblastine, and Dacarbazine (ABVD)
Number of subjects: 0
Study 36508390 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofilament light chain (NfL)
Number of subjects: 475
Study 36508390 — intervention group
Group type: EXPERIMENTAL
Intervention: Progranulin
Number of subjects: 475
Study 36508644 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular Microscope Diagnostic System (MMDx)
Number of subjects: 0
Study 36508732 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy appeal
Number of subjects: 0
Study 36508732 — intervention group
Group type: EXPERIMENTAL
Intervention: Deontological appeal
Number of subjects: 0
Study 36508732 — intervention group
Group type: EXPERIMENTAL
Intervention: Identifiable victim appeal
Number of subjects: 0
Study 36508732 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocity appeal
Number of subjects: 0
Study 36508732 — intervention group
Group type: COMPARATOR
Intervention: Control (no appeal)
Number of subjects: 0
Study 36508737 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate, High-Fat (LCHF) diet
Number of subjects: 165
Study 36508737 — intervention group
Group type: COMPARATOR
Intervention: High-Carbohydrate, Low-Fat (HCLF) diet
Number of subjects: 165
Study 36509053 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (single-dose)
Number of subjects: 301
Study 36509053 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (7-day course, standard of care)
Number of subjects: 301
Study 36509063 — intervention group
Group type: EXPERIMENTAL
Intervention: MMV390048 (120 mg)
Number of subjects: 8
Study 36509097 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocatinlimab 150 mg every 4 weeks
Number of subjects: 274
Study 36509097 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocatinlimab 600 mg every 4 weeks
Number of subjects: 274
Study 36509097 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocatinlimab 300 mg every 2 weeks
Number of subjects: 274
Study 36509097 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocatinlimab 600 mg every 2 weeks
Number of subjects: 274
Study 36509097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 36509100 — intervention group
Group type: EXPERIMENTAL
Intervention: RO7020531 (doses: 3 mg, 10 mg, 20 mg, 40 mg, 60 mg, 100 mg, 140 mg, 170 mg)
Number of subjects: 450
Study 36509100 — intervention group
Group type: EXPERIMENTAL
Intervention: RO7020531 (150 mg, 170 mg)
Number of subjects: 450
Study 36509100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 36509100 — intervention group
Group type: EXPERIMENTAL
Intervention: RO7020531 (150 mg)
Number of subjects: 450
Study 36509112 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid users
Number of subjects: 89
Study 36509112 — intervention group
Group type: COMPARATOR
Intervention: Nonusers
Number of subjects: 89
Study 36509112 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Opioid users and Nonusers)
Number of subjects: 89
Study 36509113 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast guidance
Number of subjects: 118
Study 36509113 — intervention group
Group type: COMPARATOR
Intervention: Fanning technique
Number of subjects: 118
Study 36509248 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Enhanced Single Vision Lens 01 (SESL01)
Number of subjects: 300
Study 36509248 — intervention group
Group type: COMPARATOR
Intervention: Standard single vision lenses
Number of subjects: 300
Study 36509249 — intervention group
Group type: EXPERIMENTAL
Intervention: SB with once/h 5 min walk break
Number of subjects: 56
Study 36509249 — intervention group
Group type: EXPERIMENTAL
Intervention: SB with once/h 15 min stand break
Number of subjects: 56
Study 36509249 — intervention group
Group type: EXPERIMENTAL
Intervention: SB with twice/h breaks (alternating 5 min walk and 15 min stand)
Number of subjects: 56
Study 36509249 — intervention group
Group type: COMPARATOR
Intervention: SB with no breaks (control)
Number of subjects: 56
Study 36509366 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic Fibrosis Questionnaire-Revised (CFQ-R)
Number of subjects: 400
Study 36509366 — intervention group
Group type: EXPERIMENTAL
Intervention: Time trade-off (TTO) exercise
Number of subjects: 400
Study 36509407 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks for 24 weeks (VENTURE)
Number of subjects: 0
Study 36509407 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (TRAVERSE)
Number of subjects: 0
Study 36509407 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (VENTURE)
Number of subjects: 0
Study 36509407 — intervention group
Group type: COMPARATOR
Intervention: Placebo (VENTURE)
Number of subjects: 0
Study 36509812 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT, IL-6, IP-10
Number of subjects: 581
Study 36509812 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical variables combinations
Number of subjects: 581
Study 36509812 — intervention group
Group type: EXPERIMENTAL
Intervention: CD74
Number of subjects: 581
Study 36509812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood PCT
Number of subjects: 581
Study 36509812 — intervention group
Group type: EXPERIMENTAL
Intervention: CD74 with IP-10 or clinical criterion
Number of subjects: 581
Study 36510180 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive educational intervention maintained over two years (n=51)
Number of subjects: 100
Study 36510180 — intervention group
Group type: COMPARATOR
Intervention: Only initial education (n=49)
Number of subjects: 100
Study 36510181 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPlan 2.0 digital health intervention
Number of subjects: 65
Study 36510222 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent donors (CCD)
Number of subjects: 162
Study 36510222 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbed CCD samples (n=21)
Number of subjects: 162
Study 36510222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster P1 (n=8) CCD samples
Number of subjects: 162
Study 36510234 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis protocol (mechanical, pharmacological, or combined)
Number of subjects: 884
Study 36510234 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis protocol
Number of subjects: 884
Study 36510233 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIN-HAND Program (internet-based self-guided hand exercise program)
Number of subjects: 466
Study 36510233 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 466
Study 36510237 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram
Number of subjects: 408
Study 36510237 — intervention group
Group type: EXPERIMENTAL
Intervention: nortriptyline
Number of subjects: 408
Study 36510237 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 408
Study 36510271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine plus D-PAL emulsion
Number of subjects: 130
Study 36510271 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine alone
Number of subjects: 130
Study 36510290 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam tosylate at 0.15 mg/kg
Number of subjects: 1800
Study 36510290 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam tosylate at 0.2 mg/kg
Number of subjects: 1800
Study 36510290 — intervention group
Group type: COMPARATOR
Intervention: Propofol at 1.5 mg/kg
Number of subjects: 1800
Study 36510290 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1800
Study 36510319 — intervention group
Group type: EXPERIMENTAL
Intervention: weCare/Secure intervention
Number of subjects: 1800
Study 36510319 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1800
Study 36510319 — intervention group
Group type: COMPARATOR
Intervention: Food-secure PWH
Number of subjects: 1800
Study 36510319 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-insecure PWH
Number of subjects: 1800
Study 36510324 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-lung-protective ventilation (1-2 mL/kg tidal volume, 5-10 cycles per minute, positive expiratory transpulmonary pressure, 16 hours of prone position)
Number of subjects: 39
Study 36510324 — intervention group
Group type: COMPARATOR
Intervention: Lung-protective ventilation (control group, following EOLIA trial protocol)
Number of subjects: 39
Study 36510345 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 124
Study 36510345 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal misoprostol
Number of subjects: 124
Study 36510486 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) 320/14.4/10 µg
Number of subjects: 8509
Study 36510486 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) 160/14.4/10 µg
Number of subjects: 8509
Study 36510486 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrronium/formoterol fumarate dihydrate (GFF) 14.4/10 µg
Number of subjects: 8509
Study 36510486 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol fumarate dihydrate (BFF) 320/10 µg
Number of subjects: 8509
Study 36510662 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralization of ACBP/DBI through a monoclonal antibody
Number of subjects: 0
Study 36510662 — intervention group
Group type: COMPARATOR
Intervention: High ACBP/DBI levels
Number of subjects: 0
Study 36510778 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed carcinoma (10.9% of patients, n=787)
Number of subjects: 7215
Study 36510778 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed carcinoma
Number of subjects: 7215
Study 36510826 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus intervention group 1 (IG-1)
Number of subjects: 57
Study 36510826 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus intervention group 2 (IG-2)
Number of subjects: 57
Study 36510826 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (control group, CG)
Number of subjects: 57
Study 36511149 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated plasma osteoprotegerin levels
Number of subjects: 3490
Study 36511149 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 1-SD higher log-osteoprotegerin
Number of subjects: 3490
Study 36511181 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral trimethoprim and sulfamethoxazole combined with rifampicin (administered for 2 weeks with decontamination or for 21 days with intranasal mupirocin)
Number of subjects: 135
Study 36511181 — intervention group
Group type: COMPARATOR
Intervention: Oral trimethoprim and sulfamethoxazole combined with rifampicin
Number of subjects: 135
Study 36511181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised vancomycin with oral antibiotics
Number of subjects: 135
Study 36511191 — intervention group
Group type: EXPERIMENTAL
Intervention: Original adalimumab product for 24 weeks followed by BI 695501 for 22 weeks
Number of subjects: 2
Study 36511191 — intervention group
Group type: COMPARATOR
Intervention: BI 695501 for the entire 46-week treatment period
Number of subjects: 2
Study 36511389 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate switch to tenofovir alafenamide (TAF)
Number of subjects: 34
Study 36511389 — intervention group
Group type: COMPARATOR
Intervention: Delayed switch to tenofovir alafenamide (TAF) after 48 weeks
Number of subjects: 34
Study 36511784 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 652
Study 36511784 — intervention group
Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 652
Study 36511804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer with a Gleason score of 3+4
Number of subjects: 161
Study 36511804 — intervention group
Group type: COMPARATOR
Intervention: Negative TPM results
Number of subjects: 161
Study 36511831 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniMed 780G™
Number of subjects: 0
Study 36511871 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Metric of Glycemic Control Q-Score
Number of subjects: 0
Study 36511925 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise intervention (n=414)
Number of subjects: 823
Study 36511925 — intervention group
Group type: COMPARATOR
Intervention: Attention control (n=409)
Number of subjects: 823
Study 36511925 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise intervention (n=289)
Number of subjects: 823
Study 36511925 — intervention group
Group type: COMPARATOR
Intervention: Attention control (n=273)
Number of subjects: 823
Study 36511926 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 585
Study 36511926 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 585
Study 36511926 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MBSR and exercise
Number of subjects: 585
Study 36511926 — intervention group
Group type: COMPARATOR
Intervention: Health education control group
Number of subjects: 585
Study 36511926 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes (hippocampal volume, dorsolateral prefrontal cortex thickness and surface area, functional cognitive capacity, self-reported cognitive concerns)
Number of subjects: 585
Study 36511927 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed, remotely administered behavioral lifestyle intervention (Diabetes Prevention Program-based videos, handouts, coaching messages) for 12 months
Number of subjects: 511
Study 36511927 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 511
Study 36511927 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed, remotely administered behavioral lifestyle intervention
Number of subjects: 511
Study 36512069 — intervention group
Group type: EXPERIMENTAL
Intervention: Sivopixant 50 mg
Number of subjects: 406
Study 36512069 — intervention group
Group type: EXPERIMENTAL
Intervention: Sivopixant 150 mg
Number of subjects: 406
Study 36512069 — intervention group
Group type: EXPERIMENTAL
Intervention: Sivopixant 300 mg
Number of subjects: 406
Study 36512069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 36512093 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO pathway (electronic patient-reported outcome questionnaire, blood test, and telephone consultation with a specialist nurse)
Number of subjects: 24
Study 36512093 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO pathway
Number of subjects: 24
Study 36512175 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg once daily
Number of subjects: 837
Study 36512175 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg once daily
Number of subjects: 837
Study 36512175 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib (both doses)
Number of subjects: 837
Study 36512175 — intervention group
Group type: COMPARATOR
Intervention: Dupilumab
Number of subjects: 837
Study 36512175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 837
Study 36512254 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly diagnosed DLB patients
Number of subjects: 116
Study 36512271 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder-Café intervention
Number of subjects: 109
Study 36512271 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 109
Study 36512301 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary gland cancer (SGC) patients
Number of subjects: 225
Study 36512301 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary gland cancer (SGC) patients diagnosed at stages I and IV
Number of subjects: 225
Study 36512619 — intervention group
Group type: EXPERIMENTAL
Intervention: Evocalcet low dose (1-2 mg)
Number of subjects: 313
Study 36512619 — intervention group
Group type: EXPERIMENTAL
Intervention: Evocalcet medium dose (3-4 mg)
Number of subjects: 313
Study 36512619 — intervention group
Group type: EXPERIMENTAL
Intervention: Evocalcet high dose (5-8 mg)
Number of subjects: 313
Study 36512619 — intervention group
Group type: EXPERIMENTAL
Intervention: Evocalcet (all doses)
Number of subjects: 313
Study 36512631 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Options intervention (EUDC + PST + CBT sessions)
Number of subjects: 742
Study 36512631 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care for depression (EUDC)
Number of subjects: 742
Study 36512649 — intervention group
Group type: EXPERIMENTAL
Intervention: 68 Ga-PSMA-11 PET/CT
Number of subjects: 8
Study 36512671 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-3373 (100 mg IV every other week for 12 weeks)
Number of subjects: 48
Study 36512671 — intervention group
Group type: COMPARATOR
Intervention: adalimumab (80 mg every other week for 24 weeks)
Number of subjects: 48
Study 36512671 — intervention group
Group type: COMPARATOR
Intervention: combined in-trial/historical adalimumab
Number of subjects: 48
Study 36512671 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-3373
Number of subjects: 48
Study 36512738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg once every 2 weeks plus cabozantinib 40 mg once daily (doublet arm)
Number of subjects: 71
Study 36512738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks plus cabozantinib 40 mg once daily with ipilimumab 1 mg/kg once every 6 weeks (triplet arm)
Number of subjects: 71
Study 36513051 — intervention group
Group type: EXPERIMENTAL
Intervention: On-label reduced-dose edoxaban
Number of subjects: 2448
Study 36513186 — intervention group
Group type: EXPERIMENTAL
Intervention: ARO-HSD 25 mg
Number of subjects: 18
Study 36513186 — intervention group
Group type: EXPERIMENTAL
Intervention: ARO-HSD 100 mg
Number of subjects: 18
Study 36513186 — intervention group
Group type: EXPERIMENTAL
Intervention: ARO-HSD 200 mg
Number of subjects: 18
Study 36513186 — intervention group
Group type: EXPERIMENTAL
Intervention: ARO-HSD pooled cohorts
Number of subjects: 18
Study 36513449 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (136.6 mg as aglycone equivalents)
Number of subjects: 197
Study 36513449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 36513490 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine protein supplement (twice a day for 6 weeks)
Number of subjects: 72
Study 36513490 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin supplement (twice a day for 6 weeks)
Number of subjects: 72
Study 36513490 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 72
Study 36513620 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnofertility-based relaxation, visualisation, imagination, and affirmation techniques
Number of subjects: 0
Study 36513665 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA1273
Number of subjects: 700
Study 36513665 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2
Number of subjects: 700
Study 36513815 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with Cisplatin (7.5 mg/m2)
Number of subjects: 108
Study 36513815 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
Number of subjects: 108
Study 36513852 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent diaphragm dysfunction (8% incidence)
Number of subjects: 122
Study 36513852 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent diaphragm dysfunction
Number of subjects: 122
Study 36513895 — intervention group
Group type: EXPERIMENTAL
Intervention: Ostomy Self-Management Training (OSMT) program delivered by telehealth over 5 weeks
Number of subjects: 167
Study 36513895 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 167
Study 36513991 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (anti-PD1/PDL1 or anti-CTLA4 monotherapy or combination therapy)
Number of subjects: 100
Study 36514017 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional irrigation only
Number of subjects: 80
Study 36514017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic irrigation activation system (EDDY)
Number of subjects: 80
Study 36514017 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional irrigation followed by 980-nm diode laser irradiation
Number of subjects: 80
Study 36514017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic irrigation activation system followed by 980-nm diode laser irradiation
Number of subjects: 80
Study 36514020 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile App for smoking cessation with gamification strategy
Number of subjects: 200
Study 36514020 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical practice intervention for smoking cessation
Number of subjects: 200
Study 36514019 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg tablets taken three times a day)
Number of subjects: 200
Study 36514019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 36514034 — intervention group
Group type: EXPERIMENTAL
Intervention: Ripretinib
Number of subjects: 0
Study 36514034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36514058 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with pre- and/or probiotics (FFI_PP)
Number of subjects: 2036
Study 36514058 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula without pre- and/or probiotics (FFI_noPP)
Number of subjects: 2036
Study 36514058 — intervention group
Group type: COMPARATOR
Intervention: Breastfed infants (BFI)
Number of subjects: 2036
Study 36514058 — intervention group
Group type: COMPARATOR
Intervention: Formula-fed infants (FFI)
Number of subjects: 2036